Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 22

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Anal incontinence

Recruiting

Study on the Effects of Botulinum Toxin Type A and a Drug Combination on Rectal Function in Patients with Fecal Incontinence

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Centre Hospitalier Universitaire Rouen

Strongyloidiasis

Recruiting

Study on Ivermectin for Treating Strongyloidiasis in Adults with Normal Immune Function

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ivermectin
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Intestinal ischaemia

Recruiting

Study on the Effectiveness of Oral Antibiotics Gentamicin and Metronidazole in Patients with Acute Mesenteric Ischemia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gentamicin
  • Sponsor:Assistance Publique Hopitaux De Paris

Gastrointestinal stromal tumour

Recruiting

Study on the Effectiveness of Imatinib for Patients with Intermediate-Risk Gastrointestinal Stromal Tumor and High Genomic Grade Index

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Centre Hospitalier Regional De Marseille

Anal squamous cell carcinoma

Recruiting

Study of Ezabenlimab and Drug Combination for Stage III Anal Cancer Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Centre Hospitalier Regional Universitaire

Gastrooesophageal cancer+1

Recruiting

Study on the Safety of Trifluridine/Tipiracil for Patients with Dihydropyrimidine Dehydrogenase Deficiency and Metastatic Colorectal or Gastroesophageal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Unicancer

Peritoneal mesothelioma malignant+1

Recruiting

Study of Tremelimumab for Patients with Unresectable Malignant Mesothelioma

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tremelimumab
  • Sponsor:AstraZeneca AB

Retroperitoneal fibrosis

Recruiting

Study on Stopping Prednisolone Early in Patients with Negative FDG-PET/CT and Idiopathic Retroperitoneal Fibrosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Colitis ulcerative+1

Recruiting

Study on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Prednisone
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

Study of Mirikizumab for Children with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Rectal cancer+2

Recruiting

Study of Dostarlimab Combined with Short Course Radiotherapy for Locally Advanced Rectal Cancer Patients with Microsatellite Instability

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Squamous cell carcinoma of the oral cavity+4

Recruiting

Study on the Safety and Effectiveness of Afatinib for Fanconi Anemia Patients with Advanced Squamous Cell Carcinoma in the Oral Cavity, Oropharynx, Hypopharynx, or Larynx

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Afatinib
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.